Approval · Notice of Compliance 1620 · 2004
CASODEX: Notice of Compliance 1620
Issued April 13, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1620
- Date
- April 13, 2004
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Withdrawal of indication: treatment of localized prostate cancer; and withdrawal of strength: 150mg
- Therapeutic class
- Non-steroidal anti-androgen
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CASODEX | Not yet assigned | — |
Medicinal ingredients
- BICALUTAMIDE 150 MG per TAB
- BICALUTAMIDE 50 MG per TAB